OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

BACKGROUND: In the OlympiAD study, olaparib was shown to improve progression-free survival compared with chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1 and/or BRCA2 mutation (BRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Robson, M E, Tung, N, Conte, P, Im, S -A, Senkus, E, Xu, B, Masuda, N, Delaloge, S, Li, W, Armstrong, A, Wu, W, Goessl, C, Runswick, S, Domchek, S M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/
https://www.ncbi.nlm.nih.gov/pubmed/30689707
http://dx.doi.org/10.1093/annonc/mdz012

Ejemplares similares

Ejemplares similares